41. Ervebo

Merck
(Merck)

Active ingredient: Ebola Zaire Vaccine, Live
Disease: Ebola
Peak sales estimate: n/a
Approved: Dec. 20, 2019
Company: Merck

The scoop: Merck licensed its world-first Ebola vaccine from NewLink Genetics during the worst outbreak ever and accelerated development with partners so that it could be used to fight an ongoing outbreak in the Democratic Republic of Congo. Even before its first approvals, Merck's vaccine had been used to fight the Congo outbreak that's claimed more than 2,200 lives. The shot won European approval in November, followed by a U.S. nod in December. Scientists at the Public Health Agency of Canada’s National Microbiology Laboratory originally developed the vaccine. Merck said it'll continue working with authorities to provide investigational doses as it switches to manufacturing licensed doses. Those will be available in the third quarter of 2020, Merck said. — Eric Sagonowsky

41. Ervebo

Suggested Articles

By redeploying staff, the FDA thinks it can respond to COVID-19-related requests and review protocols within 24 hours of receipt.

CRISRP Therapeutics will likely be hit by the pandemic.

Pandion will test its lead program in patients with refractory ulcerative colitis and move a second program into phase 1.